No specific guidelines included on how restrictive financial interactions should be
Pharmaceutical Commerce - April 2010
FDA-run website will provide a single point of reference
Gaps found in gray areas like adverse events reported on blogs and interactive web events
PPACA provides $3 billion in funding and creates new Patient-Centered Outcomes Research Institute
‘Pharmerging’ markets will provide half the boost to 2014’s $1.1-trillion market
Service builds on ValueCentrics’ ValueTrak channel-data tracking capability
Singapore-based Clearstate will help UBC clients navigate complex reimbursements policies
Altegrity Risk International named security partner in Closed-Loop Protection Program
Specialty pharmacy wins $61.5M in tax credits and $14M in grants for 1,000-plus jobs
‘Pharmerging’ markets will provide half the boost to 2014’s $1.1-trillion market
Blockbusters Lipitor and Plavix disappear from list due to patent expirations
90-day supplies and lower out-of-pocket expenses positively impact compliance
Reformulated drug is a ‘step in the right direction,’ says FDA director
CDC to release action plan for dealing with unused or expired swine flu vaccine
CMS will be changing reimbursement practices regardless of how healthcare reform plays out
Industry anticipates meaningful guidance from FDA on use of social media
Investment funds have developed an interest in trading capital for royalties on drug commercializations
Business, regulatory and technological conditions are constantly changing. Will your CRM/SFA system be flexible enough to keep up?
Multi-tenant sales-force automation (SFA) systems are coping with an increasingly complex regulatory environment
Converging the processes and data from EHRs and from the electronic data-capture (EDC) of the clinical research environment could change the paradigm of drug development and safety
Parenteral (injectable) drugs gain user acceptance even as biotech brings more of them onto the market
The growth of healthcare business is attracting many new players to the pharmaceutical arena, challenging pharma’s relationships with patients
PhRMA pushes for an FDA ‘universal symbol’ of approved content, and seeks latitude in communications in online forums
Big Pharma is not yet deeply enough invested in faster-growing markets outside the developed economies
Pedigree-pioneering team resurfaces with cloud-based collaborative platform
Advertisement
Advertisement
